Cargando…
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
BACKGROUND: Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. METHODS: We analy...
Autores principales: | Groisberg, Roman, Hong, David S., Behrang, Amini, Hess, Kenneth, Janku, Filip, Piha-Paul, Sarina, Naing, Aung, Fu, Siqing, Benjamin, Robert, Patel, Shreyaskumar, Somaiah, Neeta, Conley, Anthony, Meric-Bernstam, Funda, Subbiah, Vivek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735899/ https://www.ncbi.nlm.nih.gov/pubmed/29254498 http://dx.doi.org/10.1186/s40425-017-0301-y |
Ejemplares similares
-
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
por: Dembla, Vikas, et al.
Publicado: (2017) -
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018) -
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018) -
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
por: Livingston, J. Andrew, et al.
Publicado: (2016) -
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
por: Subbiah, Vivek, et al.
Publicado: (2016)